BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5235 related articles for article (PubMed ID: 15863145)

  • 1. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: "Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations".
    Olivier RI; van Beurden M
    Gynecol Oncol; 2005 Nov; 99(2):520-1. PubMed ID: 16188301
    [No Abstract]   [Full Text] [Related]  

  • 5. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
    Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
    N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
    Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
    Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR
    J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary ovarian cancer.
    Prat J; Ribé A; Gallardo A
    Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
    Casey MJ; Bewtra C
    Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
    J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
    Schrag D; Kuntz KM; Garber JE; Weeks JC
    N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
    Finch A; Shaw P; Rosen B; Murphy J; Narod SA; Colgan TJ
    Gynecol Oncol; 2006 Jan; 100(1):58-64. PubMed ID: 16137750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
    Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
    Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 262.